Updated 7 October 2026. Semaglutide is a GLP-1 receptor agonist with approved uses that differ by formulation, dose, country and patient group. Its evidence base now extends beyond glucose control and weight management to selected cardiovascular, kidney and liver-disease indications. Those approvals do not make every semaglutide product interchangeable or appropriate for every person.
What is semaglutide?
Semaglutide is an analogue of glucagon-like peptide-1 (GLP-1), a hormone involved in glucose-dependent insulin secretion, glucagon regulation, appetite and gastric emptying. Its long half-life supports once-weekly injection in some products; specific oral formulations use absorption-enhancing technology for once-daily dosing.
The medicine is marketed under different brand names for different indications. A product approved for type 2 diabetes is not automatically approved for obesity, cardiovascular-risk reduction or liver disease, even when the active ingredient is the same.
Weight-management evidence
The STEP clinical programme established that once-weekly semaglutide 2.4 mg, used with diet and physical activity, can produce clinically meaningful average weight loss in eligible adults. Individual responses vary, and gastrointestinal adverse effects and treatment discontinuation affect real-world outcomes.
In March 2026 the US FDA approved a higher-dose 7.2 mg once-weekly injection, known as Wegovy HD, for chronic weight management in certain adults. In the STEP UP trial, the company reported 20.7% average weight reduction at 72 weeks with the 7.2 mg dose under the trial’s efficacy analysis. The approval does not mean that higher doses should be improvised from other products or used without the labelled titration and medical supervision.
Cardiovascular outcomes
SELECT studied adults with established cardiovascular disease and overweight or obesity but without diabetes. Semaglutide 2.4 mg reduced the risk of the trial’s composite endpoint of cardiovascular death, non-fatal heart attack or non-fatal stroke compared with placebo. This led to a US indication for cardiovascular-risk reduction in the defined population.
The result should not be generalized to people without established cardiovascular disease or treated as proof that every semaglutide dose and formulation has the same cardiovascular indication.
Kidney outcomes in type 2 diabetes
The FLOW trial evaluated semaglutide in adults with type 2 diabetes and chronic kidney disease. Results supported a US label expansion for Ozempic to reduce the risk of kidney disease progression, kidney failure and cardiovascular death in the indicated population. Kidney outcomes, glycaemic control and weight management remain distinct treatment goals with different eligibility and monitoring needs.
MASH and liver research
In August 2025 the FDA granted accelerated approval to injectable Wegovy for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced fibrosis. The decision was based on interim histology results from the ESSENCE programme. The ongoing study is intended to determine whether these changes translate into fewer liver-related clinical events.
At EASD 2026, Novo Nordisk also presented a small post hoc STEP UP sub-study reporting reduced liver fat. Because it involved 55 participants and pooled doses, it is supportive research rather than a substitute for the dedicated MASH outcomes programme.
Oral semaglutide and new formulations
Oral semaglutide is available in specific approved tablets; it is not the same as simply putting injectable semaglutide into a capsule. Absorption is low and depends on the formulation and administration instructions. By 2026 the US portfolio included a once-daily 25 mg oral semaglutide product for chronic weight management, alongside oral semaglutide products for type 2 diabetes.
Compounded, counterfeit or “research” products should not be assumed to match an approved medicine in identity, concentration, sterility, release characteristics or clinical performance.
Safety and practical limitations
Common adverse effects include nausea, diarrhea, vomiting, constipation and abdominal discomfort, especially during dose escalation. Important labelled risks and precautions can include pancreatitis, gallbladder disease, dehydration-related kidney injury, hypoglycaemia when combined with certain diabetes medicines, diabetic-retinopathy complications in susceptible patients, and aspiration risk around anaesthesia or deep sedation.
Semaglutide products carry a warning related to thyroid C-cell tumours observed in rodents and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pregnancy planning, other medicines and planned procedures should be discussed with a qualified clinician.
Why dose and product identity matter
- Approved indications vary by product and jurisdiction.
- Dose escalation is intended to improve tolerability and should follow the current product label.
- Injectable and oral products are not dose-for-dose substitutes.
- Trial averages do not predict an individual result.
- Stopping treatment can be followed by weight regain; obesity is generally managed as a chronic condition.
Current status in 2026
Semaglutide is an established prescription medicine with a broad and evolving evidence base. The responsible description is indication-specific: approved for certain uses and populations, still under study for others. Availability and labels differ between the US, EU and individual countries, so the current local product information remains the definitive source.
Sources
- FDA: approval of higher-dose semaglutide 7.2 mg (2026)
- FDA: Wegovy approval for MASH
- FDA review of SELECT cardiovascular outcomes
- Novo Nordisk: STEP UP and Wegovy HD approval
- ClinicalTrials.gov: FLOW kidney-outcomes trial
This article is for educational reference only and is not medical advice. Prescription semaglutide should be used only for an approved indication under qualified medical supervision.
